PMID- 34676064
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231107
IS  - 2090-8083 (Print)
IS  - 2042-0080 (Electronic)
IS  - 2042-0080 (Linking)
VI  - 2021
DP  - 2021
TI  - Off Time Independently Affects Quality of Life in Advanced Parkinson's Disease 
      (APD) Patients but Not in Non-APD Patients: Results from the Self-Reported 
      Japanese Quality-of-Life Survey of Parkinson's Disease (JAQPAD) Study.
PG  - 9917539
LID - 10.1155/2021/9917539 [doi]
LID - 9917539
AB  - INTRODUCTION: Parkinson's disease (PD) is characterized by a triad of motor 
      symptoms and several nonmotor symptoms (NMS). Identifying the most appropriate 
      treatment is essential for improving patient quality of life (QoL). However, it 
      is still not known which PD symptoms more commonly affect patients with advanced 
      PD (APD) versus non-APD. This study examined the factors that most affected the 
      QoL of patients with APD (defined using the 5-2-1 criteria: >/=5 oral levodopa 
      doses a day, off time >/=2 hours a day, or troublesome dyskinesia >/=1 hour a day) 
      versus non-APD in a large Japanese population using the Japanese Quality-of-Life 
      Survey of Parkinson's Disease (JAQPAD) study. METHODS: Participants in this 
      self-reported survey-based study included all members of the Japan Parkinson's 
      Disease Association. Questionnaires assessing NMS and QoL (e.g., the 8-item PD 
      Questionnaire [PDQ-8]) were included. Univariate and multivariate regression 
      analyses were conducted to identify clinical factors impacting QoL using the 
      PDQ-8 Summary Index (PDQ-8 SI). RESULTS: Of the 3022 eligible patients, 864 were 
      classified as having non-APD and 1599 as having APD. QoL as assessed by the PDQ-8 
      SI was notably worse in patients with APD versus non-APD (39.2 vs. 26.9, p < 
      0.0001). Although off time affected QoL only in patients with APD, PD duration 
      and the NMS Questionnaire score significantly contributed to the QoL in both 
      patients with APD and non-APD. CONCLUSIONS: This study identified the factors 
      more commonly associated with worse QoL in patients with APD versus non-APD. Our 
      findings offer new insights for providing optimal treatment and improving 
      treatment satisfaction in patients with PD.
CI  - Copyright (c) 2021 Yuka Hayashi et al.
FAU - Hayashi, Yuka
AU  - Hayashi Y
AUID- ORCID: 0000-0001-8970-1978
AD  - Department of Neurology, Faculty of Medicine, Fukuoka University, 7-45-1 
      Nanakuma, Johnan-ku, Fukuoka 814-0180, Japan.
FAU - Nakagawa, Ryoko
AU  - Nakagawa R
AUID- ORCID: 0000-0002-7037-6762
AD  - Medical, AbbVie GK, 3-1-21 Shibaura, Minato-ku, Tokyo 108-0023, Japan.
FAU - Ishido, Miwako
AU  - Ishido M
AUID- ORCID: 0000-0002-8364-6856
AD  - Medical, AbbVie GK, 3-1-21 Shibaura, Minato-ku, Tokyo 108-0023, Japan.
FAU - Yoshinaga, Yoko
AU  - Yoshinaga Y
AUID- ORCID: 0000-0003-4664-0671
AD  - Medical, AbbVie GK, 3-1-21 Shibaura, Minato-ku, Tokyo 108-0023, Japan.
FAU - Watanabe, Jun
AU  - Watanabe J
AUID- ORCID: 0000-0002-4575-9358
AD  - Medical, AbbVie GK, 3-1-21 Shibaura, Minato-ku, Tokyo 108-0023, Japan.
FAU - Kurihara, Kanako
AU  - Kurihara K
AUID- ORCID: 0000-0003-1020-5053
AD  - Department of Neurology, Faculty of Medicine, Fukuoka University, 7-45-1 
      Nanakuma, Johnan-ku, Fukuoka 814-0180, Japan.
FAU - Nagaki, Koichi
AU  - Nagaki K
AUID- ORCID: 0000-0003-0519-5639
AD  - Department of Neurology, Faculty of Medicine, Fukuoka University, 7-45-1 
      Nanakuma, Johnan-ku, Fukuoka 814-0180, Japan.
FAU - Ogura, Hiromu
AU  - Ogura H
AUID- ORCID: 0000-0003-3962-8682
AD  - Department of Neurology, Faculty of Medicine, Fukuoka University, 7-45-1 
      Nanakuma, Johnan-ku, Fukuoka 814-0180, Japan.
FAU - Mishima, Takayasu
AU  - Mishima T
AUID- ORCID: 0000-0002-4649-0434
AD  - Department of Neurology, Faculty of Medicine, Fukuoka University, 7-45-1 
      Nanakuma, Johnan-ku, Fukuoka 814-0180, Japan.
FAU - Fujioka, Shinsuke
AU  - Fujioka S
AUID- ORCID: 0000-0001-9901-9008
AD  - Department of Neurology, Faculty of Medicine, Fukuoka University, 7-45-1 
      Nanakuma, Johnan-ku, Fukuoka 814-0180, Japan.
FAU - Tsuboi, Yoshio
AU  - Tsuboi Y
AUID- ORCID: 0000-0002-6758-0981
AD  - Department of Neurology, Faculty of Medicine, Fukuoka University, 7-45-1 
      Nanakuma, Johnan-ku, Fukuoka 814-0180, Japan.
LA  - eng
PT  - Journal Article
DEP - 20211012
PL  - United States
TA  - Parkinsons Dis
JT  - Parkinson's disease
JID - 101539877
PMC - PMC8526216
COIS- Y. Tsuboi has served as an advisor for AbbVie GK and has received research 
      support from the Japan Agency for Medical Research and Development and Kyowa 
      Kirin. R. Nakagawa and J. Watanabe are employees of AbbVie GK and may receive 
      stock or stock options. M. Ishido and Y. Yoshinaga are former employees of AbbVie 
      GK. Y. Hayashi, K. Kurihara, K. Nagaki, H. Ogura, T. Mishima, and S. Fujioka 
      declare no conflicts of interest.
EDAT- 2021/10/23 06:00
MHDA- 2021/10/23 06:01
PMCR- 2021/10/12
CRDT- 2021/10/22 06:50
PHST- 2021/03/17 00:00 [received]
PHST- 2021/08/10 00:00 [revised]
PHST- 2021/09/09 00:00 [accepted]
PHST- 2021/10/22 06:50 [entrez]
PHST- 2021/10/23 06:00 [pubmed]
PHST- 2021/10/23 06:01 [medline]
PHST- 2021/10/12 00:00 [pmc-release]
AID - 10.1155/2021/9917539 [doi]
PST - epublish
SO  - Parkinsons Dis. 2021 Oct 12;2021:9917539. doi: 10.1155/2021/9917539. eCollection 
      2021.